The Drive to Discover. The Experience to Deliver.
|View printer-friendly version|
|Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer|
“Jim brings extensive industry experience to
“Jakafi is a novel, first-in-class product that is making a remarkable difference for patients with this debilitating condition,” stated Mr. Daly. “I’m excited by Incyte’s cutting-edge science and the potential commercial value of its substantial pipeline. Incyte’s leadership position in the development of oral JAK inhibitors to address unmet needs in a wide range of grievous illnesses represents a unique opportunity. I look forward to joining the team, building on its success with Jakafi and contributing to the development and commercialization of Incyte’s future products.”
Prior to joining
Previously, Mr. Daly spent 17 years with Glaxo Wellcome/GlaxoSmithKline
(GSK) where he advanced through numerous positions of increasing
Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.
Important Safety Information
Jakafi can cause serious side effects including:
Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests.
Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.
The most common side effects of Jakafi include dizziness and headache.
These are not all the possible side effects of Jakafi. Ask your healthcare provider or pharmacist for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Before taking Jakafi, tell your healthcare provider about all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had liver or kidney problems, are on dialysis, or have any other medical condition. Talk to your healthcare provider before drinking grapefruit juice while taking Jakafi.
Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.
For Full Prescribing Information for Jakafi, visit www.Jakafi.com.
Except for the historical information set forth herein, the matters set
forth in this press release, including without limitation statements
with respect to our plans and expectations with respect to Jakafi®
(ruxolitinib), including the potential efficacy and therapeutic and
commercial value of Jakafi, and the advancement of our pipeline, contain
predictions, estimates and other forward-looking statements. These
forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including unanticipated
developments in and risks related to the efficacy or safety of Jakafi,
the high degree of risk and uncertainty associated with drug development
and the regulatory approval process, and other risks detailed from time
to time in our reports filed with the
Jakafi is a registered trademark of
The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.
- Stock Information
- Earnings Estimates
- Quarterly Results
- Press Releases
- Analysts Coverage
- Events & Webcasts
- Annual Reports
- Proxy Information
- SEC Filings
- Corporate Governance
- Investor FAQ
- Information Request
- Contact Us